Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 165

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 7
Chunk 165
---
•$62.3 million decrease due to the prior year divestitures of the Rare Diseases Business and the Hospital & Specialty Business and the sale of branded products; partially offset by

•$23.7 million increase from favorable foreign currency translation;

•$8.2 million increase, or 0.7%, due primarily to growth of $15.1 million in the Pain & Sleep Aids category led by restored supply of the Solpadeine® brand, partially offset by unfavorable impacts across multiple OTC businesses due to soft category consumption, including lower net sales of $12.5 million in the VMS category.

CSCI net sales by product category were as follows:

SalesNine Months Ended(in millions, except percentages)September 27, 2025September 28, 2024$ Change% ChangeSkin Care$326.1 $333.5 $(7.4)(2.2)%Upper Respiratory209.5 206.0 3.5 1.7 %Healthy Lifestyle180.2 175.2 4.9 2.8 %Pain and Sleep-Aids173.4 158.6 14.9 9.4 %VMS116.2 127.4 (11.2)(8.8)%Women's Health103.3 101.2 2.2 2.2 %Oral Care71.6 75.0 (3.4)(4.6)%Digestive Health30.1 27.0 3.1 11.5 %Other CSCI44.7 81.5 (37.0)(45.3)%Total CSCI$1,255.1 $1,285.5 $(30.4)(2.4)%

Sales in each category were driven primarily by: 

•Skin Care: Net sales of $326.1 million decreased 2.2%, inclusive of a 1.2% favorable effect of currency translation, due primarily to soft seasonal consumption trends compared to the prior year and the unfavorable impact of 2.0% from divested businesses and exited product lines. These factors were partially offset by share growth in Compeed® and Sebamed®, despite the soft seasonal trends;

50

Perrigo Company plc - Item 2CSCI

•Upper Respiratory: Net sales of $209.5 million increased 1.7%, inclusive of a 2.6%